WallStSmart

Henry Schein Inc (HSIC)vsPfizer Inc (PFE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Pfizer Inc generates 373% more annual revenue ($63.32B vs $13.38B). PFE leads profitability with a 11.8% profit margin vs 3.0%. HSIC appears more attractively valued with a PEG of 1.79. PFE earns a higher WallStSmart Score of 55/100 (C).

HSIC

Buy

52

out of 100

Grade: C-

Growth: 4.7Profit: 5.5Value: 6.7Quality: 5.0
Piotroski: 2/9Altman Z: 2.37

PFE

Buy

55

out of 100

Grade: C

Growth: 3.3Profit: 7.0Value: 4.7Quality: 5.5
Piotroski: 4/9Altman Z: 1.70
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

HSICUndervalued (+46.8%)

Margin of Safety

+46.8%

Fair Value

$153.40

Current Price

$77.45

$75.95 discount

UndervaluedFair: $153.40Overvalued
PFEUndervalued (+13.8%)

Margin of Safety

+13.8%

Fair Value

$30.21

Current Price

$26.04

$4.17 discount

UndervaluedFair: $30.21Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HSIC1 strengths · Avg: 8.0/10
Price/BookValuation
2.7x8/10

Reasonable price relative to book value

PFE4 strengths · Avg: 8.8/10
Operating MarginProfitability
31.6%10/10

Strong operational efficiency at 31.6%

Market CapQuality
$145.62B9/10

Large-cap with strong market position

Price/BookValuation
1.6x8/10

Reasonable price relative to book value

Free Cash FlowQuality
$2.18B8/10

Generating 2.2B in free cash flow

Areas to Watch

HSIC4 concerns · Avg: 3.5/10
PEG RatioValuation
1.794/10

Expensive relative to growth rate

EPS GrowthGrowth
4.5%4/10

4.5% earnings growth

Profit MarginProfitability
3.0%3/10

3.0% margin — thin

Debt/EquityHealth
1.153/10

Elevated debt levels

PFE3 concerns · Avg: 2.7/10
Altman Z-ScoreHealth
1.704/10

Distress zone — elevated risk

PEG RatioValuation
13.772/10

Expensive relative to growth rate

EPS GrowthGrowth
-10.1%2/10

Earnings declined 10.1%

Comparative Analysis Report

WallStSmart Research

Bull Case : HSIC

The strongest argument for HSIC centers on Price/Book.

Bull Case : PFE

The strongest argument for PFE centers on Operating Margin, Market Cap, Price/Book.

Bear Case : HSIC

The primary concerns for HSIC are PEG Ratio, EPS Growth, Profit Margin. Thin 3.0% margins leave little buffer for downturns.

Bear Case : PFE

The primary concerns for PFE are Altman Z-Score, PEG Ratio, EPS Growth.

Key Dynamics to Monitor

HSIC carries more volatility with a beta of 0.82 — expect wider price swings.

HSIC is growing revenue faster at 6.3% — sustainability is the question.

PFE generates stronger free cash flow (2.2B), providing more financial flexibility.

Monitor MEDICAL DISTRIBUTION industry trends, competitive dynamics, and regulatory changes.

Bottom Line

PFE scores higher overall (55/100 vs 52/100). HSIC offers better value entry with a 46.8% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Henry Schein Inc

HEALTHCARE · MEDICAL DISTRIBUTION · USA

Henry Schein, Inc. is an American distributor of health care products and services with a presence in 32 countries.

Visit Website →

Pfizer Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.

Visit Website →

Want to dig deeper into these stocks?